Novo Nordisk Drug Shows Significant Weight Loss in Women
A new post hoc analysis reveals CagriSema patients lost an average of 25 percent of their body weight over 68 weeks.
Updated on Oct. 20, 2026 in Weight Loss
Live Poll
Do you believe weight loss drugs are an effective long-term health solution?
Novo Nordisk reported that its experimental drug, CagriSema, resulted in a 25 percent average weight loss among women in a clinical trial. The findings were presented at The Menopause Society annual meeting.
Why it matters
The study suggests that hormonal changes during different menopausal stages may influence weight loss outcomes for patients taking the medication. This analysis provides deeper insight into the efficacy of the treatment for diverse groups of women.
In the REDEFINE 1 trial, premenopausal women lost 26.7 percent of their body weight, compared to 24.8 percent for perimenopausal women and 23.1 percent for postmenopausal women. These figures reflect results from a 2.4 milligram dose.
The players
Novo Nordisk
This is a global pharmaceutical company headquartered in Denmark that specializes in diabetes and weight management treatments.
The Menopause Society
This is a nonprofit organization dedicated to promoting the health and quality of life of all women during midlife and beyond.
The details
Researchers evaluated weight loss across 1,902 women within the larger 3,400-person REDEFINE 1 study. The weekly injection, which combines cagrilintide and semaglutide, was tested over a 68-week duration to measure total body mass reduction.
Timeline
68 weeks was the total duration of the CagriSema weight loss study.
October 20, 2026, was the date of the data presentation at The Menopause Society meeting.
The fourth quarter of 2026 is the timeframe for an expected US FDA approval decision.
Health Landscape
This analysis extends findings from the REDEFINE 1 clinical trial to categorize effectiveness by menopausal status. It marks a shift toward more granular reporting on how hormonal stages influence the results of weight management therapies.
Patients may see improved weight management options if the drug receives regulatory approval in late 2026. Consult with a healthcare provider to determine how current medical guidelines apply to individual weight loss goals.
The takeaway
These findings highlight the potential for personalized approaches to obesity treatment based on life stage. Future developments in this class of medication could offer more precise outcomes for women seeking weight management solutions.
What happens next
A US FDA decision on the approval of CagriSema is expected in the fourth quarter of 2026.
Further reading
For more information on clinical research trends, visit the Weight Loss section.
Live Poll
Do you believe weight loss drugs are an effective long-term health solution?
